Impact of time from transplant to treatment of patients with refractory cytomegalovirus infection: post hoc analysis of Phase 3 SOLTICE study

被引：0
|
作者：
Chemaly, R.
Avery, R.
Dadwal, S.
Kamar, N.
Maertens, J.
Papanicolaou, G. A.
Witzke, O.
Gu, J.
Auciello, J.
机构：
来源：
SWISS MEDICAL WEEKLY | 2022年 / 152卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P24
引用
收藏
页码：8S / 8S
页数：1
相关论文
共 50 条
  • [21] Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
    Kiladjian, Jean-Jacques
    Vannucchi, Alessandro M.
    Gerds, Aaron T.
    Gupta, Vikas
    Verstovsek, Srdan
    Egyed, Miklos
    Platzbecker, Uwe
    Mayer, Jiri
    Grosicki, Sebastian
    Illes, Arpad
    Wozny, Tomasz
    Oh, Stephen T.
    McLornan, Donal
    Kirgner, Ilya
    Yoon, Sung-Soo
    Harrison, Claire N.
    Klencke, Barbara
    Huang, Mei
    Kawashima, Jun
    Mesa, Ruben
    HEMASPHERE, 2023, 7 (11): : E963
  • [22] Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized Phase 3 REACH2 Study
    Socie, Gerard
    Xue, Zhenyi
    Bhatt, Valkal
    Galvin, John
    Mohty, Mohamad
    BLOOD, 2022, 140 : 4765 - 4766
  • [23] Efficacy Of Rituximab In Patients With Refractory Lupus Nephritis, a Post-Hoc Analysis From Phase II Trial In Japan.
    Tanaka, Yoshiya
    Yamamoto, Kazuhiko
    Takeuchi, Tsutomu
    Miyasaka, Nobuyuki
    Sumida, Takayuki
    Mimori, Tsuneyo
    Koike, Takao
    Endo, Kazuhiro
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S253 - S254
  • [24] Phase 3 Study of Maribavir (MBV) vs. Investigator-Assigned Therapy (IAT) for Refractory/Resistant (R/R) Cytomegalovirus (CMV) Infection Post-Transplant: Analysis of Kidney Recipients and Renal Safety
    Shihab, Fuad S.
    Avery, Robin K.
    Blumberg, Emily
    Haririan, Abdolreza
    Wu, Jingyang
    Sundberg, Aimee K.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 17 - 17
  • [25] Healthcare Resource Utilization in Transplant Recipients With Cytomegalovirus Infection Refractory to Prior Treatment With/Without Resistance Receiving Maribavir Versus Investigatorassigned Therapy: Exploratory Analysis of the Phase 3 SOLSTICE Trial
    Hirji, Ishan
    Cocks, Kim
    Moreno-Koehler, Alejandro
    Sundberg, Aimee
    TRANSPLANTATION, 2022, 106 (09) : S746 - S747
  • [26] The impact of fremanezumab treatment on depression severity in patients with concomitant antidepressant use: post hoc analysis of the UNITE study
    Barbanti, P.
    Tassorelli, C.
    Campos, V. Ramirez
    Krasenbaum, L. J.
    Akcicek, H.
    Ortega, M.
    Burstein, R.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [27] Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia
    Parry, Helen Marie
    Damery, Sarah
    Hudson, Christopher
    Maurer, Matthew J.
    Cerhan, James R.
    Pachnio, Annette
    Begum, Jusnara
    Slager, Susan L.
    Fegan, Christopher
    Man, Stephen
    Pepper, Christopher
    Shanafelt, Tait D.
    Pratt, Guy
    Moss, Paul A. H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (08) : 776 - 781
  • [28] POST-TRANSPLANT CYTOMEGALOVIRUS INFECTION IN HEMATOLOGICAL PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION: IMPACT OF NOVEL THERAPIES
    Juarez Salcedo, L. M.
    Gutierrez-Jomarron, I.
    Garcia-Suarez, J.
    Gil-Fernandez, J. J.
    Magro Mazo, E.
    Marcellini Antonio, S.
    Casco Amarilla, C.
    Cortti Ferrari, M. J.
    Martin Guerrero, Y.
    Callejas Charavia, M.
    Flores Ballester, E.
    Arribas, I.
    Lopez-Rubio, M.
    Calero, M. A.
    Pascual, T.
    Burgaleta Alonso de Ozalla, C.
    HAEMATOLOGICA, 2014, 99 : 715 - 715
  • [29] CHARACTERISTICS OF RESPONDERS AND NON-RESPONDERS TO TREATMENT WITH SUCROFERRIC OXYHYDROXIDE: A POST HOC ANALYSIS OF A PHASE 3 STUDY
    Floege, Juergen
    Sprague, Stuart
    Rastogi, Anjay
    Ketteler, Markus
    Covic, Adrian
    Rakov, Viatcheslav
    Larroque, Sylvain
    Pergola, Pablo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 1466 - 1466
  • [30] Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study
    Pereira, M.
    Silveira, F.
    Papanicolaou, G.
    Langston, A.
    Avery, R.
    Wijatyk, A.
    Wu, J.
    Boeckh, M.
    Marty, F.
    Villano, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 405 - 405
12345